Oncotarget

Research Papers: Pathology:

CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases

Jie Xu, L. Jeffrey Medeiros, Annapurna Saksena, Michael Wang, Jiehao Zhou, Jingyi Li, C. Cameron Yin, Guilin Tang, Lifu Wang, Pei Lin and Shaoying Li _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:11441-11450. https://doi.org/10.18632/oncotarget.23571

Metrics: PDF 1401 views  |   HTML 2778 views  |   ?  


Abstract

Jie Xu1, L. Jeffrey Medeiros1, Annapurna Saksena1, Michael Wang2, Jiehao Zhou3, Jingyi Li1,4, C. Cameron Yin1, Guilin Tang1, Lifu Wang1,5, Pei Lin1 and Shaoying Li1

1Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA

2Department of Lymphoma and Myeloma, UT MD Anderson Cancer Center, Houston, TX, USA

3Department of Pathology, Indiana University, Indianapolis, IN, USA

4Department of Hematology, Tianjin First Center Hospital, China

5Department of Pathology, Henan Provincial People's Hospital, Zhengzhou, Henan, China

Correspondence to:

Shaoying Li, email: [email protected]

Keywords: CD10; mantle cell lymphoma; pathology; prognosis

Received: August 18, 2017     Accepted: October 13, 2017     Published: December 15, 2017

ABSTRACT

Mantle cell lymphoma is usually negative for CD10 which is useful in distinguishing MCL from other CD10 + B cell lymphomas. Here we assessed the clinicopathologic features of 30 cases of CD10+ MCL, the largest series to date in the English literature, and compared them with a group of 212 typical MCL cases (CD5+, CD10-negative, CD23-negative, cyclin D1+). The 30 patients with CD10+ MCL included 17 men and 13 women with a median age of 68 years. Compared with CD10-negative MCL, patients with CD10+ MCL showed a lower male predominance (p = 0.01), more often had a diffuse growth pattern (p = 0.04) and blastoid/pleomorphic morphology (p < 0.0001), and more often showed BCL6 expression (p = 0.009). In all MCL patients, CD10 expression was not associated with overall survival (OS) (p = 0.16). However, in more aggressive subsets of MCL patients including those with high Ki67 (> 60%), blastoid/pleomorphic morphology, or high MCL International Prognostic Index (MIPI), CD10 expression was associated with a worse OS (p = 0.003, 0.04, and 0.001, respectively). High Ki67 (> 60%), blastoid/pleomorphic morphology, and high MIPI were also been identified as poor prognostic factors patients with in CD10+ MCL (p = 0.001, 0.0003, and 0.01, respectively). In summary, CD10+ MCL more often has a diffuse growth pattern, blastoid/pleomorphic morphology, and BCL6 expression. In MCL patients with a high Ki-67 (> 60%), blastoid/pleomorphic morphology, or high MIPI, CD10 expression contributes to an even worse prognosis. MCL should be included in the differential diagnosis of CD10 + B cell lymphomas.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23571